Sign In
Buy VBIV
$0.0653
+0 (+0%)
At Close: Nov 15, 2024
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
08:00am, Thursday, 26'th Oct 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ
VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
07:49am, Wednesday, 27'th Sep 2023
VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.
VBI Vaccines' Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
07:30am, Wednesday, 27'th Sep 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is str
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
10:00am, Tuesday, 22'nd Aug 2023
First patient dosed in a PEG-IFN -α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enrichin
VBI Vaccines Reports Second Quarter 2023 Financial Results
08:00am, Monday, 14'th Aug 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid
VBI Vaccines Announces Closing of Underwriters' Partial Exercise of Option to Purchase Additional Common Shares
08:00am, Monday, 24'th Jul 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseas
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
08:00am, Wednesday, 19'th Jul 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ
7 Biotech Stocks to Sell in July
07:00am, Thursday, 13'th Jul 2023
Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.
Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
09:05am, Thursday, 06'th Jul 2023
VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
10:41am, Monday, 15'th May 2023
VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
12:56pm, Wednesday, 05'th Apr 2023
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
08:14am, Tuesday, 04'th Apr 2023
VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates
10:44am, Monday, 13'th Mar 2023
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
12:48pm, Thursday, 13'th Oct 2022
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
